“默沙東中國(guó)”近日發(fā)布消息稱，其九價(jià)人乳頭瘤病毒疫苗（九價(jià)HPV疫苗）的新適應(yīng)證已獲得中國(guó)國(guó)家藥品監(jiān)督管理局批準(zhǔn)，此次獲批標(biāo)志著默沙東九價(jià)HPV疫苗在國(guó)內(nèi)適用人群拓展至9-45歲適齡女性。

China's top drug regulator has expanded the use of an imported vaccine against nine strains of the cancer-causing human papillomavirus to girls as young as nine and adults up to age 45.

中國(guó)國(guó)家藥品監(jiān)督管理局近日批準(zhǔn)將九價(jià)人乳頭瘤病毒疫苗（九價(jià)HPV疫苗）在國(guó)內(nèi)適用人群拓展至9-45歲適齡女性。

The National Medical Products Administration first granted authorization to Gardasil 9, a 9-valent HPV vaccine created by global pharmaceutical giant Merck, for use in females aged 16 to 26 in 2018. On Tuesday, the administration said that its use is now broadened to females aged 9 through 45.

2018年，國(guó)家藥品監(jiān)督管理局首次批準(zhǔn)全球制藥巨頭默克公司研發(fā)的9價(jià)HPV疫苗“加衛(wèi)苗”上市，適用于16-26歲的女性。8月30日，國(guó)家藥品監(jiān)督管理局表示，該疫苗在國(guó)內(nèi)適用人群拓展至9-45歲適齡女性。

In China, nearly 110,000 women were diagnosed with cervical cancer last year, and 59,000 had died of the disease, said Zhao Fanghui, a professor at the National Cancer Center and Chinese Academy of Medical Sciences' Cancer Hospital, citing data from the Global Cancer Observatory, a cancer data platform associated with the World Health Organization.

國(guó)家癌癥中心、中國(guó)醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院教授趙方輝援引全球癌癥觀察的數(shù)據(jù)說(shuō)，中國(guó)去年有近11萬(wàn)名女性確診宮頸癌，5.9萬(wàn)人因患宮頸癌去世。全球癌癥觀察是隸屬于世界衛(wèi)生組織的癌癥數(shù)據(jù)平臺(tái)。

Eliminating the disease would require consolidated efforts in boosting the vaccination rate, especially among those aged under 15, as well as promoting early screening and treatment. Due to limited supplies and low awareness, China is now lagging far behind some leading countries in terms of immunization coverage, according to Zhao.

趙方輝表示，消除宮頸癌需要大力提高疫苗接種率，特別是在15歲以下適齡人群中，并推進(jìn)宮頸癌的早期篩查和治療。由于疫苗供應(yīng)有限以及人們的認(rèn)識(shí)不足，中國(guó)目前在疫苗接種率方面遠(yuǎn)遠(yuǎn)落后于一些領(lǐng)先國(guó)家。

However, the rising number of highly effective domestic vaccines available on the market is expected to ramp up the efforts.

但是，隨著市面上高效的國(guó)產(chǎn)疫苗數(shù)量的增加，疫苗接種率有望進(jìn)一步提高。

A new study published in the journal The Lancet Infectious Disease on Friday shows that Cecolin, the first domestic vaccine that protects against two HPV strains, is 100 percent effective in protecting against genital lesions－a precancerous condition－and 97.3 percent effective against persistent infection.

8月26日發(fā)表在《柳葉刀-感染病學(xué)》期刊上的最新研究報(bào)告顯示，首個(gè)國(guó)產(chǎn)二價(jià)HPV疫苗馨可寧對(duì)宮頸癌癌前病變的保護(hù)效果可達(dá)到100%，還可預(yù)防97.3%的HPV持續(xù)感染。

來(lái)源：中國(guó)日?qǐng)?bào)

編輯：yaning